IRVINE, Calif., Sept. 12, 2006 (PRIMEZONE) -- "Companies looking to capture market share in the multi-billion dollar pharmaceutical industry are aggressively adding brands to their arsenal of products while continuing proprietary in-house drug development," stated SmallCap Sentinel analyst, D.R. Clark. "Using effective integrated marketing schemes, companies can acquire existing and profitable brands, blending their distribution and sales with a success architecture already in place for other products."
"Along these lines, Auriga Laboratories(tm), Inc. (OTCBB:ARGA) has just announced that the company has acquired an exclusive license to market the popular Levall family of common cold remedy prescription drug products from Athlon Pharmaceuticals in a transaction worth up to $20 million," Clark added.
Auriga Laboratories, Inc., a specialty pharmaceutical company, engages in the development and marketing of prescription products for drugs using drug delivery technologies and reformulation strategies. It offers Extendryl(R), a prescription cough/cold medication. The company's products address disease treatment in various areas, such as cough and cold medications, gastrointestinal disorders, and central nervous system disorders. Auriga Laboratories is based in Norcross, Georgia.
The Levall product line includes four trademarked lines that address medical needs in the multibillion-dollar market for respiratory and common cold ailments. The existing Levall products treat symptoms such as cough, chest congestion and stuffy nose from the common cold, flu, or other breathing illnesses such as sinusitis and bronchitis. Levall generated approximately $9.7 million of sales in 2005 and $9.6 million of sales in 2004 while owned by Athlon.
The informational report "The Silver Tsunami: Baby Boomers & Biotech Breakthroughs" has been made available free of charge via financial courier StockUpTicks.com at www.SmallCapSentinel.com.
The report will detail various issues affecting the current market for biotechnology and pharmaceutical companies including Baxter International Inc. (NYSE:BAX), Intuitive Surgical Inc (Nasdaq:ISRG), ev3, Inc. (Nasdaq:EVVV) and Auriga Laboratories.
Individuals may also register for future reports at: http://stockupticks.com/register.html
Statements made herein contain forward-looking statements and are subject to significant risks and uncertainties that affect results. SmallCap Sentinel and StockUpTicks.com are properties of Market Pathways Financial Relations Inc. (MP). MP provides no assurance as to the subject company's plans or ability to effect any proposed actions and cannot project capabilities, intent, resources, or experience. All information contained herein is based upon sources believed to be reliable but no representation is made as to its accuracy or completeness. This report is neither a solicitation to buy, nor offer to sell securities but is rather a paid advertisement provided for information purposes only and should not be used as the basis for any investment decision. MP is not an investment advisor and this report is not investment advice. MP has been paid $1,500 by Auriga Laboratories for preparation and distribution of this report and other advertising services. This constitutes a conflict of interest as to MP's ability to remain objective in its communication regarding the subject companies.